PortfoliosLab logoPortfoliosLab logo
ARCT vs. SRRK
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ARCT vs. SRRK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcturus Therapeutics Holdings Inc. (ARCT) and Scholar Rock Holding Corporation (SRRK). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ARCT achieves a 16.15% return, which is significantly higher than SRRK's -0.57% return.


ARCT

1D
-2.47%
1M
-22.78%
YTD
16.15%
6M
-4.43%
1Y
-44.33%
3Y*
-36.26%
5Y*
-26.90%
10Y*

SRRK

1D
-1.13%
1M
-9.49%
YTD
-0.57%
6M
-3.20%
1Y
27.96%
3Y*
84.27%
5Y*
8.97%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

ARCT vs. SRRK - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
ARCT
Arcturus Therapeutics Holdings Inc.
16.15%-63.88%-46.18%85.91%-54.17%-14.68%155.18%
SRRK
Scholar Rock Holding Corporation
-0.57%1.92%129.89%107.73%-63.57%-48.82%220.54%

Correlation

The correlation between ARCT and SRRK is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.25

Correlation (3Y)
Calculated over the trailing 3-year period

0.32

Correlation (5Y)
Calculated over the trailing 5-year period

0.38

Correlation (All Time)
Calculated using the full available price history since Apr 17, 2020

0.36

The correlation between ARCT and SRRK shifts across timeframes, from 0.25 (1 year) to 0.38 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

ARCT:

$202.36M

SRRK:

$5.57B

EPS

ARCT:

-$1.81

SRRK:

-$3.49

PB Ratio

ARCT:

1.06

SRRK:

20.20

Total Revenue (TTM)

ARCT:

$46.80M

SRRK:

$0.00

Gross Profit (TTM)

ARCT:

$40.72M

SRRK:

-$1.27M

EBITDA (TTM)

ARCT:

-$84.61M

SRRK:

-$394.71M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ARCT vs. SRRK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARCT
ARCT Risk / Return Rank: 2525
Overall Rank
ARCT Sharpe Ratio Rank: 2121
Sharpe Ratio Rank
ARCT Sortino Ratio Rank: 2828
Sortino Ratio Rank
ARCT Omega Ratio Rank: 2727
Omega Ratio Rank
ARCT Calmar Ratio Rank: 2121
Calmar Ratio Rank
ARCT Martin Ratio Rank: 2626
Martin Ratio Rank

SRRK
SRRK Risk / Return Rank: 5959
Overall Rank
SRRK Sharpe Ratio Rank: 5858
Sharpe Ratio Rank
SRRK Sortino Ratio Rank: 6161
Sortino Ratio Rank
SRRK Omega Ratio Rank: 5757
Omega Ratio Rank
SRRK Calmar Ratio Rank: 6060
Calmar Ratio Rank
SRRK Martin Ratio Rank: 6161
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ARCT vs. SRRK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcturus Therapeutics Holdings Inc. (ARCT) and Scholar Rock Holding Corporation (SRRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ARCTSRRKDifference
Sharpe ratioReturn per unit of total volatility

-0.91

Sortino ratioReturn per unit of downside risk

-1.35

Omega ratioGain probability vs. loss probability

0.98

1.14

-0.16

Calmar ratioReturn relative to maximum drawdown

-0.60

0.81

-1.40

Martin ratioReturn relative to average drawdown

-0.83

1.92

-2.75

ARCT vs. SRRK - Sharpe Ratio Comparison

The current ARCT Sharpe Ratio is -0.48, which is lower than the SRRK Sharpe Ratio of 0.43. The chart below compares the historical Sharpe Ratios of ARCT and SRRK, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


ARCTSRRKDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.48

0.43

-0.91

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.29

0.05

-0.34

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.13

0.09

-0.22

Drawdowns

ARCT vs. SRRK - Drawdown Comparison

The maximum ARCT drawdown since its inception was -95.23%, roughly equal to the maximum SRRK drawdown of -93.15%. Use the drawdown chart below to compare losses from any high point for ARCT and SRRK.


Loading charts...

Drawdown Indicators


ARCTSRRKDifference

Max Drawdown

Largest peak-to-trough decline

-95.23%

-93.15%

-2.08%

Max Drawdown (1Y)

Largest decline over 1 year

-74.53%

-34.86%

-39.67%

Max Drawdown (3Y)

Largest decline over 3 years

-86.71%

-65.21%

-21.50%

Max Drawdown (5Y)

Largest decline over 5 years

-89.87%

-88.96%

-0.91%

Current Drawdown

Current decline from peak

-94.24%

-35.61%

-58.63%

Average Drawdown

Average peak-to-trough decline

-73.02%

-56.44%

-16.58%

Ulcer Index

Depth and duration of drawdowns from previous peaks

53.28%

14.61%

+38.67%

Volatility

ARCT vs. SRRK - Volatility Comparison

Arcturus Therapeutics Holdings Inc. (ARCT) has a higher volatility of 19.67% compared to Scholar Rock Holding Corporation (SRRK) at 13.58%. This indicates that ARCT's price experiences larger fluctuations and is considered to be riskier than SRRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ARCTSRRKDifference

Volatility (1M)

Calculated over the trailing 1-month period

19.67%

13.58%

+6.09%

Volatility (6M)

Calculated over the trailing 6-month period

41.10%

35.86%

+5.24%

Volatility (1Y)

Calculated over the trailing 1-year period

92.73%

65.55%

+27.18%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

91.85%

180.23%

-88.38%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

102.23%

157.72%

-55.49%

Dividends

ARCT vs. SRRK - Dividend Comparison

Neither ARCT nor SRRK has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ARCT vs. SRRK - Financials Comparison

This section allows you to compare key financial metrics between Arcturus Therapeutics Holdings Inc. and Scholar Rock Holding Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M20222023202420252026
2.06M
0
(ARCT) Total Revenue
(SRRK) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ARCT and SRRK have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ARCT has higher volatility (19.67%) compared to SRRK (13.58%). In terms of maximum drawdown, ARCT dropped -95.23% vs SRRK's -93.15%.

SRRK currently has the higher Sharpe Ratio (0.43 vs -0.48), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ARCT and SRRK

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer